NCT06730347 - A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2027

Conditions

Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaClear Cell Adenocarcinoma of OvaryClear Cell Adenocarcinoma of VulvaClear Cell Adenocarcinoma of VaginaClear Cell Adenocarcinoma of CervixClear Cell Adenocarcinoma of UterusClear Cell Adenocarcinoma of Fallopian TubeClear Cell Adenocarcinoma of PeritoneumEndometrial Cancer

Interventions

BIOLOGICAL

Lorigerlimab

Bispecific DART protein binding PD-1 and CTLA-4

Trial Locations (16)

15224

NOT_YET_RECRUITING

West Penn Allegheny Health, Pittsburgh

49546

RECRUITING

START Midwest, Grand Rapids

53705

RECRUITING

Wisconsin Institute Medical Research- UW Cancer Connect, Madison

70115

RECRUITING

Ochsner MD Anderson Cancer Center, New Orleans

77030

RECRUITING

Mays Clinic, Houston

78229

RECRUITING

START San Antonio, San Antonio

90095

RECRUITING

UCLA, Los Angeles

M5G 2M9

NOT_YET_RECRUITING

Princess Margaret Cancer Center, Toronto

H4A3J1

RECRUITING

McGill University, Montreal

410-763

NOT_YET_RECRUITING

National Cancer Center, Goyang-si

463-707

NOT_YET_RECRUITING

Seoul National University Hospital Bundang Hospital, Seongnam-si

03722

NOT_YET_RECRUITING

Yonsei University Health System Severance Hospital, Seoul

06273

RECRUITING

Gangnam Severance Hospital, Seoul

08308

NOT_YET_RECRUITING

Korea University Guro Hospital, Seoul

110-74

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

135-710

NOT_YET_RECRUITING

Samsung Medical Center, Seoul